Roivant Sciences Ltd.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.
Your own DCF model
A full discounted-cash-flow model of Roivant Sciences Ltd., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Biotechnology
Multiples of its companies with a market value at most 60 days old, times Roivant Sciences Ltd.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Roivant Sciences Ltd. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 2.2× / 5.0× / 10.1× | — | revenue $8 M | $19 M to $83 M | 85 |
| Price to book | 3.1× / 4.5× / 12.3× | 5.8× | book equity $4.5 B | $14.0 B to $55.8 B | 70 |
Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.
Against its own history
Roivant Sciences Ltd.'s multiples at each month end with a market cap on file, Jan 2024 to Oct 2026, each against its own median.
Price to sales
786.2×Now above its median of 278.4×, in the top quarter of its range; range 223.4× to 786.2× over 16 months.
Price to book
5.8×Now above its median of 2.9×, in the top quarter of its range; range 1.3× to 7.5× over 24 months.
as of Oct 27, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 27, 2026.
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Mar 31, 2026 | $8 M | $-300 M | $-750 M | $8 M | $-759 M | — | SEC annual report (10-K, 20-F) |
| FY2024to Mar 31, 2025 | $29 M | $-172 M | $-839 M | $5 M | $-844 M | — | SEC annual report (10-K, 20-F) |
| FY2023to Mar 31, 2024 | $33 M | $4.3 B | $-765 M | $1 M | $-767 M | $-6.1 B | SEC annual report (10-K, 20-F) |
| FY2022to Mar 31, 2023 | $32 M | $-1.0 B | $-843 M | $13 M | $-856 M | $-1.3 B | SEC annual report (10-K, 20-F) |
| FY2021to Mar 31, 2022 | $55 M | $-845 M | $-678 M | $17 M | $-695 M | $-1.9 B | SEC annual report (10-K, 20-F) |
| FY2020to Mar 31, 2021 | $24 M | $-809 M | $-552 M | $6 M | $-558 M | $-1.9 B | SEC annual report (10-K, 20-F) |
Each figure as filed; the full statements with every line and its filing are on the company page. Market value $26.1 B on Oct 27, 2026.
How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.